AKTX Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Release of the Next CEO Corner Segment

16 days ago - By: Akari Therapeutics Plc

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

24 days ago - By: Akari Therapeutics Plc

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

a month ago - By: Benzinga - Mentions: RIGL RDHL VCYT RARE ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

a year ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Key Leadership Appointments

a month ago - By: Benzinga - Mentions: SLNO SSRM RIGL NVVE ...

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

a month ago - By: Akari Therapeutics Plc

Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

a month ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

a month ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Launch of CEO Corner Platform

2 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

2 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

2 months ago - By: Akari Therapeutics Plc

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

3 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

3 months ago - By: Akari Therapeutics Plc

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Akari Therapeutics Plc

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

4 months ago - By: Akari Therapeutics Plc

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

4 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

4 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

4 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

4 months ago - By: ACCESS Newswire - Mentions: AMIX CNSP NVNO GRI ...

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

6 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

6 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

7 months ago - By: Akari Therapeutics Plc

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

7 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

8 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

8 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

9 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

10 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

10 months ago - By: Akari Therapeutics Plc

Akari Therapeutics Joins Webull Corporate Connect Service Platform

a year ago - By: Akari Therapeutics Plc

AKARI THERAPEUTICS PLC-ADR (AKTX) Stock News

AKTX Latest News, Press Relases and Analysis

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Akari Therapeutics Announces Key Leadership Appointments

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Akari Therapeutics Announces Launch of CEO Corner Platform

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer